Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer

This publication has 18 references indexed in Scilit:

• Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines
  British Journal of Cancer, 1996
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
  Journal of Clinical Oncology, 1994
• Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
  Journal of Clinical Oncology, 1994
• Characterization of an etoposide-resistant human ovarian cancer cell line
  Cancer Chemotherapy and Pharmacology, 1994
• Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.
  Journal of Clinical Oncology, 1993
• Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer
  Gynecologic Oncology, 1992
• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
  BMJ, 1991
• Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
  Journal of Clinical Oncology, 1989
• Phase II trial of VP-16-213 in advanced ovarian carcinoma
  Gynecologic Oncology, 1985